ABOUT THE BIOTECH CEO SUMMITS – UNLIKE ANY OTHER CONFERENCE
The Biotech CEO Summits are unlike most other meetings CEOs attend. The Summits focus on the participating CEOs discussing issues of importance to them as leaders of companies they want to position for growth and success. The Summits are discussion based meetings led by subject matter experts. All participants are invited to, and indeed encouraged to join the discussions by asking questions and sharing their personal insights. The Summits are run under Chatham House Rules to encourage open and frank conversation. The media are not invited, and the sessions are not recorded, to provide an extra layer of privacy.
2023 Agenda
Monday, June 12
| 14:00 |
Registration: Main Lobby |
| 16:30 |
Icebreaker Activity – Wine & Chocolate Pairing: Dolce Vita Patio Networking & wine tasting led by Judit Llop, chief winemaker, in the Cava, Montsant, Catalunya and Priorat wine regions & a pairing with Simón Coll chocolates. |
| 18:45 |
Welcome & Opening Remarks: Dolce Vita Garden Sara Jane Demy, Founder & CEO, Demy-Colton |
| 19:00 |
CEO Summit Participant Introductions: Dolce Vita Garden All participants are invited to briefly introduce themselves. |
| 19:30 |
Fireside Chat Series: Dolce Vita Garden The Purposeful CEO – Fulfilling the Promise CEOs of biotech companies strive to bring therapeutics to patients in a challenging environment where the rules are still being written and the outcomes are still experimental.
|
| 20:15 | Networking Reception & Dinner: Pool Deck |
Tuesday, June 13
| 07:00 |
Private Networking Breakfast: Entre Venias Patio |
| 08:30 |
Summit Overview & Rules of Engagement: Ra Conference Room |
| 08:45 |
The Pulse of European Biotechnology: Braving the Headwinds & Moving Forward Three years after the start of the pandemic (where European companies played a leading role in developing technology and treatments) we are still dealing with the overhang of a global economic downturn that has led to fragility in the banking sector; a more cautious venture environment; and a war in Eastern Europe. Despite these setbacks, the biotech sector in Europe has and continues to demonstrate its position as a leader in global biotech innovation. Discussion Leader:
Discussants:
|
|
09:30 |
Defining Your Corporate Strategy: Making Sense of the Options Charting a course for your company means making bold decisions. Potential strategies for your company may include “going-it-alone” for development and commercialization or a range of potential partnering pathways. This discussion will explore key options, their relative pros and cons, and how to prioritize the best ones, given your company’s objectives. Discussion Leader:
Discussants:
|
| 10:15 |
Networking Break: Dolce Vita Garden |
|
10:45 |
Building Value Through the Company Lifecycle: The Key to Successful BD and Fundraising Things like planning for market access and commercialization may seem premature for an early-stage biotech but can be instrumental in maximizing value in preparation for any strategic pathway, whether that involves a transaction and exit or commercialization. Potential partners will want to understand the target asset value propositions (clinical/scientific, economic, and commercial) and the market potential of an asset of interest to them. And, from the investor’s point of view, these value propositions and market data drive their investment interest. Discussion Leader:
Discussants:
|
| 11:30 |
Asset Value: The Need to Think Globally to Stay Ahead of The Game
Discussants:
|
| 12:15 |
Networking Lunch: Seaview Terraza |
| 13:45 |
Enterprise and Asset Valuation: The Difference and What’s Really Important Understanding valuation and how to use it to your advantage is a key aspect for any biotech company that is raising money (an ongoing process), licensing assets or looking for an M&A transaction. But valuation is not only for transactions, it is key for strategic purposes. We will discuss what the key value drivers are; how the value can be optimized; what investors, buyers and licensing partners are focused on; and how valuation informs strategic decisions.
Discussants:
|
| 14:30 |
Fundraising: An Open Discussion – Why Persistence Pays Raising money for an innovative company at any stage is always challenging. Let’s discuss the options including staying private vs going public, debt versus equity. We will also discuss how to attract and engage investors aligned with your company’s roadmap.
Discussants:
|
| 14:50 |
Fundraising: Breakout: Art Rooms
Discussants:
Discussion Leader (Public):
Discussants:
|
| 15:30 |
Thinking Like Investors: Understanding Decision Drivers and Motivations for the Range of Funding Sources
Discussants:
|
| 16:15 |
How Will the Proposed EU Regulatory Changes and the US Inflation Reduction Act (IRA) Affect Your Business?
|
| 17:00 |
Day 1 Wrap-Up & Instructions for CEO Summit Games
|
| 17:30 |
Biotech CEO Summit Europe Games – Flamenco Battle and Giant Jenga: Entre Venias Patio Please wear comfortable shoes and clothes |
| 19:30 | Break |
| 20:00 | Biotech CEO Summit Europe Awards & Dinner: Beach Club |
Wednesday, June 14
| 07:00 |
Private Networking Breakfast: Entre Venias Patio |
| 08:30 |
Welcome Back & Day 2 Commences: Ra Conference Room Sara Jane Demy, Founder & CEO, Demy-Colton |
| 08:45 |
Communications: A Tool to Help Build and Maintain Your Company’s Reputation for Potential Partners, Investors and Patients
|
| 09:45 |
Business and Boards: Building Trust and Engagement to Support Success
Discussants:
|
| 10:45 | Networking Break : Dolce Vita Garden |
| 11:00 |
Building a Smart Team & Keeping Them: The Essentials for Success
Discussants:
|
| 12:00 | Networking Lunch: Seaview Terraza |
| 13:00 |
The Reality and Rewards of Being a CEO Who Leads Through Difficult Times
Discussant:
|
| 14:00 |
An Unguarded Conversation Among Friends Is being a biotech CEO really the loneliest job in the world? |
| 14:30 |
Wrap Up Biotech CEO Summit Sara Jane Demy, Founder & CEO, Demy-Colton |
| 14:45 |
Closing Reception: Dolce Vita Garden |